These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38882995)

  • 1. Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital.
    Agnihotri A; Ramasubbu SK; Bandyopadhyay A; Bidarolli M; Nath UK; Das B
    Cureus; 2024 May; 16(5):e60492. PubMed ID: 38882995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
    Khan Q; Ismail M; Khan S
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
    Khan Q; Ismail M; Haider I; Ali Z
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
    Khan Q; Ismail M; Haider I; Khan F
    Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.
    Das B; Ramasubbu SK; Agnihotri A; Kumar B; Rawat VS
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211058892. PubMed ID: 34841978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients.
    Das B; Ramasubbu SK; Kumar B; Rawat VS
    J Family Med Prim Care; 2020 Dec; 9(12):6023-6040. PubMed ID: 33681037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
    Vandael E; De WuLf I; Foulon V
    J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
    Khan Q; Ismail M; Haider I
    Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
    Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
    J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis.
    Ramasubbu SK; Mishra A; Mandal S
    J Pharm Pract; 2024 Feb; 37(1):162-168. PubMed ID: 35968552
    [No Abstract]   [Full Text] [Related]  

  • 13. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.
    Meid AD; Bighelli I; Mächler S; Mikus G; Carrà G; Castellazzi M; Lucii C; Martinotti G; Nosè M; Ostuzzi G; Barbui C; Haefeli WE
    Ther Adv Psychopharmacol; 2017 Dec; 7(12):251-264. PubMed ID: 29201344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study.
    Khan Q; Ismail M; Haider I; Haq IU; Noor S
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1511-1518. PubMed ID: 28803378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer.
    Rowe EJ; Shugg T; Ly RC; Philips S; Rosenman MB; Callaghan JT; Radovich M; Overholser BR; Schneider BP; Tisdale JE; Skaar TC
    Front Cardiovasc Med; 2022; 9():894623. PubMed ID: 36588548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.
    Franchi C; Ardoino I; Rossio R; Nobili A; Biganzoli EM; Marengoni A; Marcucci M; Pasina L; Tettamanti M; Corrao S; Mannucci PM;
    Drugs Aging; 2016 Jan; 33(1):53-61. PubMed ID: 26693921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.
    Giraud EL; Ferrier KRM; Lankheet NAG; Desar IME; Steeghs N; Beukema RJ; van Erp NP; Smolders EJ
    Lancet Oncol; 2022 Sep; 23(9):e406-e415. PubMed ID: 36055309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study.
    Ali Z; Ismail M; Nazar Z; Khan F; Khan Q; Noor S
    BMC Psychiatry; 2020 Jun; 20(1):277. PubMed ID: 32493330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.